Literature DB >> 12842343

Characterisation of drug release from cubosomes using the pressure ultrafiltration method.

Ben J Boyd1.   

Abstract

Cubosomes have been proposed as a controlled release, intravenous drug delivery system. The objective of this study was to characterise cubosomes as either a therapeutically useful, controlled release delivery system, or as a burst release carrier such as submicron emulsions. The pressure ultrafiltration method and equilibrium dialysis were used to elucidate the in vitro drug release mechanisms. On dilution of cubosomes, lipophilic compounds were released rapidly when studied by the pressure ultrafiltration method. This agrees with the behaviour predicted from simple diffusion from the bulk non-dispersed cubic phase. In contrast, equilibrium dialysis incorrectly indicated sustained drug release from cubosomes. This study illustrates that cubosomes should be classified as a burst release delivery system where drug is released by diffusion from the cubic phase matrix, and that pressure ultrafiltration may have benefits over dialysis methods for measurement of drug release from colloidal particle-based drug delivery systems.

Mesh:

Substances:

Year:  2003        PMID: 12842343     DOI: 10.1016/s0378-5173(03)00262-x

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  31 in total

1.  Formulation of dacarbazine-loaded cubosomes. Part III. Physicochemical characterization.

Authors:  Di Bei; Tao Zhang; James B Murowchick; Bi-Botti C Youan
Journal:  AAPS PharmSciTech       Date:  2010-08-06       Impact factor: 3.246

2.  Reverse hexagonal phase nanodispersion of monoolein and oleic acid for topical delivery of peptides: in vitro and in vivo skin penetration of cyclosporin A.

Authors:  Luciana B Lopes; Denise A Ferreira; Daniel de Paula; M Tereza J Garcia; José A Thomazini; Márcia C A Fantini; M Vitória L B Bentley
Journal:  Pharm Res       Date:  2006-05-25       Impact factor: 4.200

Review 3.  Cubic phases of ternary amphiphile-water systems.

Authors:  Scott Fraser; Frances Separovic; Anastasios Polyzos
Journal:  Eur Biophys J       Date:  2009-06-16       Impact factor: 1.733

4.  Formulation of dacarbazine-loaded cubosomes-part I: influence of formulation variables.

Authors:  Di Bei; Jacob Marszalek; Bi-Botti C Youan
Journal:  AAPS PharmSciTech       Date:  2009-08-11       Impact factor: 3.246

Review 5.  Cubosomes: The Next Generation of Smart Lipid Nanoparticles?

Authors:  Hanna M G Barriga; Margaret N Holme; Molly M Stevens
Journal:  Angew Chem Int Ed Engl       Date:  2018-09-26       Impact factor: 15.336

6.  Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation.

Authors:  Stephanie J Wallace; Jian Li; Roger L Nation; Richard J Prankerd; Ben J Boyd
Journal:  J Pharm Sci       Date:  2012-05-23       Impact factor: 3.534

7.  Comparative study on the suitability of two techniques for measuring the transfer of lipophilic drug models from lipid nanoparticles to lipophilic acceptors.

Authors:  Mohamed Dawoud; Fahima M Hashem
Journal:  AAPS PharmSciTech       Date:  2014-08-16       Impact factor: 3.246

8.  In vitro lipolysis data does not adequately predict the in vivo performance of lipid-based drug delivery systems containing fenofibrate.

Authors:  Nicky Thomas; Katharina Richter; Thomas B Pedersen; René Holm; Anette Müllertz; Thomas Rades
Journal:  AAPS J       Date:  2014-04-02       Impact factor: 4.009

9.  Nanostructured reverse hexagonal liquid crystals sustain plasma concentrations for a poorly water-soluble drug after oral administration.

Authors:  Tri-Hung Nguyen; Tracey Hanley; Christopher J H Porter; Ben J Boyd
Journal:  Drug Deliv Transl Res       Date:  2011-12       Impact factor: 4.617

10.  Oleoylethanolamide-based lyotropic liquid crystals as vehicles for delivery of amino acids in aqueous environment.

Authors:  Sayed Z Mohammady; Matthieu Pouzot; Raffaele Mezzenga
Journal:  Biophys J       Date:  2009-02-18       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.